Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Multiple claims are not fully supported or are presented in a misleading way relative to the label. Key safety language (all-cause mortality) appears to be framed as causality rather than an observed association, and several other claims lack required label support or exceed the specificity provided in the supplied labeling text.
Category Scores
Accurate Statements
Proper dosing includes an initial 100 mg loading dose, followed by 50 mg every 12 hours.
2.1 Recommended Adult Dosage: initial dose of 100 mg followed by 50 mg every 12 hours.
The label discusses an increase in all-cause mortality observed in a meta-analysis of Phase 3 and 4 trials and that the cause has not been established.
Boxed Warning (All-Cause Mortality): observed increase in all-cause mortality; cause not established.
TYGACIL should be reserved for use when alternative treatments are not suitable.
Boxed Warning (All-Cause Mortality): 'TYGACIL should be reserved for use in situations when alternative treatments are not suitable'.
TYGACIL prescribing in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases risk of development of drug-resistant bacteria.
5.12 Development of Drug-Resistant Bacteria.
Unsupported Statements
Tigecycline is approved for complicated skin infections.
The supplied label text includes no explicit indication statements in the '1 INDICATIONS AND USAGE' section content; only the boxed warning references 1.4.
Tigecycline is approved for intra-abdominal infections.
No explicit indication wording is provided in the supplied label text.
Tigecycline is approved for community-acquired pneumonia.
No explicit indication wording is provided in the supplied label text.
The FDA issued a black-box warning for tigecycline in 2010.
No issuance date is provided in the supplied labeling text.
Pooled clinical trial data showed all-cause mortality was 4.0% in the tigecycline group versus 3.0% in controls.
The supplied boxed warning provides a 0.6% risk difference (95% CI 0.1, 1.2) but does not provide 4.0% vs 3.0% values.
The difference in all-cause mortality was driven largely by patients who received tigecycline for off-label or unapproved uses.
No such explanation is provided in the supplied boxed warning or other provided excerpts.
When tigecycline is used outside its approved indications, efficacy drops.
While 5.12 addresses lack of benefit when not prescribing in the absence of proven/strongly suspected bacterial infection, it does not support a general claim about off-label/approved-indication efficacy.
When tigecycline is used outside its approved indications, risk rises.
No label support is provided for a general 'outside approved indications increases risk' statement; 5.12 specifically addresses lack of proven/suspected bacterial infection and resistance risk.
Tigecycline efficacy against pseudomonas species is unreliable.
No organism-specific efficacy statements are included in the supplied labeling text.
Tigecycline efficacy against proteus species is unreliable.
No organism-specific efficacy statements are included in the supplied labeling text.
Tigecycline efficacy against blood-stream infections is low.
No indication-specific or infection-site efficacy statements are included in the supplied labeling text.
Proper dosing of tigecycline includes a 100 mg loading dose.
Not unsupported (supported). (This entry is included only if the evaluation required; however, it is supported by 2.1, so it should not be here. Removing from this list.)
Underdosing tigecycline allows bacteria to survive and develop resistance.
The label excerpt supports resistance risk when prescribing in the absence of proven/strongly suspected bacterial infection, but does not support underdosing-specific resistance development.
Overdosing tigecycline increases side effects.
No overdose/overdosing relationship is provided in the supplied labeling text.
Severe liver enzyme elevations can lead to fatalities with ignored dose rules.
5.4 discusses hepatic dysfunction/failure and monitoring, but does not link fatalities to 'ignored dose rules' or support dose-rule causation.
Pancreatitis can lead to fatalities with ignored dose rules.
5.5 states fatal cases occurred with tigecycline, but does not link fatality to ignored dose rules.
Superinfection with difficile colitis can lead to fatalities with ignored dose rules.
5.9 states CDAD may range to fatal colitis; it does not connect this to 'ignored dose rules' and uses CDAD terminology rather than 'superinfection' wording.
Common side effects of tigecycline include nausea and vomiting.
No adverse reaction frequency or 'common side effects' statement is included in the supplied label excerpts.
Nausea and vomiting can lead to dehydration and inability to receive the intravenous drug.
No such causal chain or support is provided in the supplied label excerpts.
Nausea is 20–30% higher in tigecycline users than in control groups.
No comparative nausea incidence data is provided in the supplied label excerpts.
Severe nausea and vomiting can lead to inability to receive the intravenous drug.
No such statement is provided in the supplied label excerpts.
Tigecycline efficacy against pseudomonas species is unreliable.
No organism-specific efficacy statement is provided in the supplied label excerpts.
Tigecycline efficacy against proteus species is unreliable.
No organism-specific efficacy statement is provided in the supplied label excerpts.
Tigecycline efficacy against blood-stream infections is low.
No blood-stream infection efficacy statement is provided in the supplied label excerpts.
Contradictions
Low
AI Statement
TYGACIL increases all-cause mortality; therefore it should be reserved for use when alternative treatments are not suitable.
Label Reference
Boxed Warning (All-Cause Mortality): 'An increase in all-cause mortality has been observed... The cause of this mortality risk difference... has not been established. TYGACIL should be reserved...'
Important Omissions
When discussing the boxed warning, include that the mortality observation is an observed increase and that the cause has not been established (avoid implying established causality).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant claims are not supported by the provided label excerpts (e.g., quantitative mortality rates, off-label use explanation, 'ignored dose rules' fatality linkage). One mortality statement risks misleading framing of causality versus an observed association.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are unsupported by the supplied prescribing information excerpts, and the boxed-warning mortality statement is framed with potentially misleading causal language.
Suggested Improvement
Restrict claims to what the supplied label text states (e.g., use the boxed-warning wording: observed increase; cause not established; reserve when alternatives are not suitable). Remove or rephrase unsupported quantitative comparisons and dose-rule/cause-of-fatality assertions not present in the provided labeling.